September 2026 Research Update

This month added a clearer real-world picture of who tends to show an early oxalate drop after starting lumasiran (an RNA interference medicine that lowers oxalate production). In a French cohort, most patients with primary hyperoxaluria type 1 met an early response target by 3 months, and the strongest pattern was that children did better than adults. By contrast, grouping patients by genotype linked to vitamin B6 (pyridoxine) sensitivity did not clearly separate responders from non-responders. [1]

The study reported that 73% of patients with available data met a composite 3-month endpoint based on urine oxalate or plasma oxalate (depending on kidney function). Age at diagnosis and age at lumasiran start were the main measured factors tied to response, with the best responses in pediatric patients. The authors also noted there was not a statistically significant relationship between genotype group and response, although they described a trend toward less response in vitamin B6-sensitive forms. [1]

For patients and families, these results mainly add reassurance about what is being seen outside of clinical trials: many people show a meaningful early drop in oxalate measures after starting lumasiran, and children may be more likely to meet early response targets. This does not mean any one person will respond the same way, but it helps set expectations that age can matter when looking at early lab changes. The study focused on short-term response at 3 months, so it does not answer longer-term questions like kidney outcomes for different age groups. [1]

This month, studies looking at genetics highlighted two practical messages: in some regions, a small number of gene changes explain many cases, while other work is still exploratory and trying to understand why disease complications differ between patients. A large Moroccan series found a high yield from a stepwise approach that starts by checking certain AGXT gene regions first, reflecting a strong founder mutation in that population. A separate small study combined patient DNA sequencing with a rat model to generate early candidate genes that might relate to kidney stone susceptibility, but it needs confirmation in larger groups. [2] [3]

In 132 Moroccan patients evaluated over 10 years, first-line testing focused on AGXT exons identified biallelic disease-causing or likely disease-causing variants in 72% of patients, and the final genetic diagnosis rate reached 78%. The most frequent change was a recurrent AGXT variant (c.731T>C, p.Ile244Thr), consistent with a founder effect, which is why the authors supported an exon-focused workflow in that population. The report also noted a limitation: biochemical confirmation (such as urine testing) was absent or incomplete for some patients, which can affect certainty about diagnosis in a real-world setting. [2]

In the smaller exploratory study, eight patients with primary hyperoxaluria type 1 had whole-exome sequencing, and researchers also examined gene activity changes in a primary hyperoxaluria rat model. They reported sets of genes related to cell structure, cell adhesion, cell-cycle processes, and immune response, and they described 22 genes that differed in distribution between patients with and without kidney stones in this small sample. Because of the very small number of patients, the findings are best understood as a shortlist of possibilities rather than an explanation that is ready to apply to individual patients. [3]

For families seeking a genetic answer, the Moroccan study supports the idea that testing strategies can be tailored to the local pattern of common variants, which may help some people get answers faster in that region. At the same time, the exploratory sequencing work on kidney stones is not something used for day-to-day care yet; it is early research trying to map out why complications like stones may vary across people with the same main diagnosis. Together, these studies clarify what is already strong (population-specific diagnostic yield) and what is still uncertain (the additional genes that might influence kidney stone risk). [2] [3]

One report this month focused on medical education rather than primary hyperoxaluria. It evaluated an online, French-language quiz program designed to improve physician recognition of the causes of AA amyloidosis. Because it studied a different disease, it does not add direct evidence about diagnosing or treating primary hyperoxaluria. [4]

Across 2,597 analyzed quiz responses, the overall correct response rate was 62.1%, with wide variation depending on the specific cause being tested, and participants who completed the satisfaction survey rated the program highly. The main result is that physicians engaged with the format and performance differed by topic area within AA amyloidosis. These findings are about clinician learning patterns rather than patient outcomes. [4]

For people following primary hyperoxaluria research, this study mainly serves as context that physician training tools are being tested in rare kidney-related conditions, but it does not address primary hyperoxaluria symptoms, genetic testing, or treatments. It does not change what is known about primary hyperoxaluria this month, and its results are most relevant to how continuing medical education can be delivered and measured. [4]